ATAI Life Sciences NV (ATAI)
1.17
-0.02
(-1.68%)
USD |
NASDAQ |
Sep 27, 16:00
1.175
0.00 (0.00%)
After-Hours: 20:00
ATAI Life Sciences Cash from Operations (Quarterly): -16.23M for June 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -16.23M |
| March 31, 2024 | -22.57M |
| December 31, 2023 | -21.96M |
| September 30, 2023 | -18.43M |
| June 30, 2023 | -22.61M |
| March 31, 2023 | -21.11M |
| December 31, 2022 | -30.50M |
| September 30, 2022 | -28.04M |
| June 30, 2022 | -21.93M |
| Date | Value |
|---|---|
| March 31, 2022 | -23.99M |
| December 31, 2021 | -20.51M |
| September 30, 2021 | -28.11M |
| June 30, 2021 | 1.897M |
| March 31, 2021 | -16.52M |
| December 31, 2020 | -6.214M |
| September 30, 2020 | -5.445M |
| June 30, 2020 | -5.218M |
| March 31, 2020 | -3.889M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-30.50M
Minimum
Dec 2022
1.897M
Maximum
Jun 2021
-17.30M
Average
-20.81M
Median
Cash from Operations (Quarterly) Benchmarks
| Affimed NV | -17.55M |
| InflaRx NV | -12.93M |
| BioNTech SE | 1.755B |
| Immatics NV | -35.46M |
| CureVac NV | -95.04M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 16.30M |
| Cash from Financing (Quarterly) | 0.326M |
| Free Cash Flow | -79.22M |
| Free Cash Flow Per Share (Quarterly) | -0.1012 |
| Free Cash Flow to Equity (Quarterly) | -15.13M |
| Free Cash Flow to Firm (Quarterly) | -15.64M |
| Free Cash Flow Yield | -40.74% |